OTCMKTS:PMCBD PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis $0.94 -0.02 (-2.19%) As of 08/29/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About PharmaCyte Biotech Stock (OTCMKTS:PMCBD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PharmaCyte Biotech alerts:Sign Up Key Stats Today's Range$0.93▼$0.9750-Day Range$0.83▼$1.1152-Week Range$5.56▼$55.50Volume33,507 shsAverage Volume8,831 shsMarket Capitalization$1.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA. Read More Receive PMCBD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMCBD Stock News HeadlinesPharmaCyte Biotech (PMCB) Earnings Dates & ReportsSeptember 27, 2024 | investing.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024March 19, 2024 | investorplace.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.September 1 at 2:00 AM | Brownstone Research (Ad)PharmaCyte Biotech Inc (PMCB)February 22, 2024 | investing.comExploring beauty’s biotech frontierOctober 27, 2023 | ft.comPMCB PharmaCyte Biotech, Inc.May 25, 2023 | seekingalpha.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferMay 11, 2023 | marketwatch.comBaltimore Biotech NewsApril 28, 2023 | bizjournals.comSee More Headlines PMCBD Stock Analysis - Frequently Asked Questions How have PMCBD shares performed this year? PharmaCyte Biotech's stock was trading at $1.55 on January 1st, 2025. Since then, PMCBD shares have decreased by 39.4% and is now trading at $0.9390. How do I buy shares of PharmaCyte Biotech? Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:PMCBD CIKN/A Webwww.pharmacyte.com Phone(917) 595-2850FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.09% Return on Assets-43.39% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,671,000Free FloatN/AMarket Cap$1.57 million OptionableNot Optionable Beta0.27 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:PMCBD) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMCBD Stock Alerts